

Rosemary Townsend,<sup>1</sup> Asma Khalil,<sup>1</sup> Yaamini Premakumar,<sup>1</sup> John Allotey,<sup>2</sup> Kvm I.E. Snell<sup>4</sup>; Claire Chan<sup>3</sup>; Lucv C Chappell,<sup>7</sup> Richard Hooper<sup>3</sup>, Marcus Green,<sup>5</sup> Ben W. Mol,<sup>6</sup> Basky Thilaganathan,<sup>1</sup> Shakila Thanagaratnam<sup>2</sup> On behalf of the IPPIC Network

1. Molecular and Clinical Sciences Research Institute, St George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK
2. Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
3. Pragmatic Clinical Trials Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
5. Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK
6. Action on Pre-eclampsia (APEC) Charity, Worcestershire. UK
7. Department of Obstetrics and Gynaecology, School of Medicine, Monash University, Melbourne, Australia
8. Department of Women and Children's Health, King's College London, London, UK

## Corresponding author

Dr Asma Khalil  
Fetal Medicine Unit  
St George's University of London  
London SW17 0RE  
E-mail: [akhalil@sgul.ac.uk](mailto:akhalil@sgul.ac.uk)

**Keywords:** Pre-eclampsia; screening; prediction; hypertension in pregnancy; systematic review

**Short title:** Prediction of pre-eclampsia: Review of reviews

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/uog.20117

IPPIC Network:

John Allotey;<sup>1,2,3</sup> Kym Snell;<sup>4</sup> Claire Chan;<sup>2</sup> Richard Hopper;<sup>2</sup> Julie Dodds;<sup>1,2,3</sup> Ewelina Rogozinska;<sup>1,2,3</sup> Khalid Khan;<sup>1,2,3</sup> Lucilla Poston;<sup>5</sup> Louise Kenny;<sup>6</sup> Jenny Myers;<sup>7</sup> Basky Thilaganathan;<sup>8</sup> Lucy Chappell;<sup>9</sup> Ben W. Mol;<sup>10</sup> Peter Von Dadelszen;<sup>9</sup> Asif Ahmed;<sup>11</sup> Marcus Green;<sup>12</sup> Asma Khalil;<sup>8</sup> Karel Moons;<sup>13</sup> Richard D. Riley;<sup>4</sup> Shakila Thangaratinam;<sup>1,2,3</sup>

<sup>1</sup> Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

<sup>2</sup> Pragmatic Clinical Trials Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

<sup>3</sup> Multidisciplinary Evidence Synthesis Hub (MESH), Queen Mary University of London, London, UK

<sup>4</sup> Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK

<sup>5</sup> Division of Women's Health, Women's Health Academic Centre, King's College London, London, UK

<sup>6</sup> Irish Centre for Fetal and Neonatal Translational Research [INFANT], University College Cork, Ireland

<sup>7</sup> Maternal & Fetal Health Research Centre, Manchester Academic Health Science Centre, University of Manchester, Central Manchester NHS Trust, Manchester, UK

<sup>8</sup> Fetal Medicine Unit, St George's Hospital, St George's University of London, London, UK

<sup>9</sup> Department of Women and Children's Health, King's College London, London, UK

<sup>10</sup> Department of Obstetrics and Gynaecology, School of Medicine, Monash University, Melbourne, Australia

<sup>11</sup> Aston Medical School, Aston University, Birmingham, UK

<sup>12</sup> Action on Pre-eclampsia (APEC) Charity, Worcestershire. UK

<sup>13</sup> Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, the Netherlands

## ABSTRACT

**Objective:** Primary studies and systematic reviews provide varied accuracy estimates for prediction of pre-eclampsia. We undertook a review of published systematic reviews to collate published evidence on the ability of available tests to predict pre-eclampsia, to identify high value avenues for future research and to minimise future research waste in this field.

**Methods:** We searched Medline, Embase, DARE (Database of Abstracts of Reviews of Effectiveness) and Cochrane Library databases (from database inception to March 2017) and bibliographies for systematic reviews and meta-analyses without language restrictions. We assessed the quality of the included reviews using the AMSTAR tool and a modified QUIPS tool. We evaluated the reviews' comprehensiveness of search, size, tests and outcomes evaluated, data synthesis methods and predictive ability estimates and risk of bias related to population studied, measurement of predictors and outcomes, study attrition and adjustment for confounding.

**Results:** From 2444 citations, we included 126 reviews, reporting on over 90 predictors and 52 prediction models. Around a third of all reviews (29.3%, 37/126) investigated biochemical markers for predicting pre-eclampsia; 24.6% (31/126) investigated genetic associations with pre-eclampsia, 36.5% (46/126) reported on clinical characteristics; 3.2% (4/126) evaluated only ultrasound markers; and 4.8% (6/126) studied a combination of tests. Reviews included between two and 265 primary studies, including up to 25,356,688 women in the

largest review. Only half (67/126, 53.2%) assessed the quality of the included studies. There was a high risk of bias in many of the included reviews, particularly in relation to population representativeness and study attrition. Over 80% (106/126, 84.1%) summarised the findings with meta-analysis. Thirty-four studies (32/126, 25.4%) lacked a formal statement on funding. The predictors with the best test performance were body mass index (BMI>35 specificity 92%, 95% CI 89-95% and sensitivity 21%, 95% CI: 12-31%; BMI >25 specificity 73% , 95% CI: 64-83% and sensitivity 47% , 95%CI: 33-61%), first trimester uterine artery Doppler PI or RI >90<sup>th</sup> centile (specificity 93%, 95% CI: 90%-96%) and sensitivity 26% (23-31%)), PLGF (specificity 89% , 95% CI: 89-89% and sensitivity 65% , 95% CI: 63-67%) and PP13 (specificity 88% , 95% CI: 87-89% and sensitivity 37% , 95% CI: 33-41%). No single marker had a test performance suitable for routine clinical use. The models combining markers showed promise, but none of the identified models had undergone external validation.

Conclusion: Our review of reviews has questioned the need for further aggregate meta-analysis in this area, given the large number of published reviews subject to the common limitations of primary predictive studies. Prospective, well-designed studies of predictive markers, preferably in randomised intervention studies, and combined through IPD (individual patient data) meta-analysis are needed to develop and validate new prediction models to facilitate the prediction of pre-eclampsia and minimise further research waste in this field.

## INTRODUCTION

Pre-eclampsia remains a major contributor to maternal and perinatal mortality and morbidity.<sup>(1,2)</sup> Early treatment with aspirin reduces the risk of pre-eclampsia;<sup>(3,4)</sup> so accurate screening tests for pre-eclampsia are a clinical priority. Currently, clinical assessment of the risk of pre-eclampsia is based mainly on maternal history<sup>(5)</sup> with limited predictive ability,<sup>(6–8)</sup> and is not applicable to nulliparous women. Numerous primary studies have evaluated the predictive ability of various tests including clinical characteristics, biomarkers, and ultrasound markers, individually or in combination, for predicting early, late, and any onset pre-eclampsia.

Systematic reviews collate evidence and aim to provide meaningful summary estimates of the predictive ability of tests through meta-analysis. Despite the number of published studies of predictive factors and screening tests for pre-eclampsia, no consensus has been reached; neither clinicians nor national or international guidelines have implemented screening tests in routine clinical practice. This could be because no tests have been identified with adequate performance, but can also be attributed to the variable quality of the reviews. Very few validate existing prediction models<sup>(9)</sup> or report on test performance in various combinations, for different thresholds and outcomes.

There is a need to map and critically appraise the available evidence in this field to minimise research waste and prioritise robust investigation of high yield predictive factors and models. We undertook a review of systematic reviews to

systematically collate and critically evaluate the published systematic reviews on risk factors identified as predictors for pre-eclampsia and the reported ability of individual tests to predict pre-eclampsia.

## METHODS

Our review of reviews was based on a prospective protocol according to current recommendations<sup>(10–12)</sup> and reported as per the PRISMA guidelines<sup>(13)</sup>. The study was registered with the PROSPERO database (CRD42015020386, <http://www.crd.york.ac.uk/PROSPERO>).

### *Literature search*

We searched Medline, Embase and the Cochrane Library including The Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), The Cochrane Central Register of Controlled Trials (CENTRAL), Health Technology Assessment Database (HTA) and NHS Economic Evaluation Database (NHS-EED) from inception to March 2017. We used combinations of the relevant medical subject heading (MeSH) terms, key words, and word variants for “pre-eclampsia”, “gestational hypertension”, “pregnancy-induced hypertension” and “review” (Supplementary Material). No language restrictions were imposed. Reference lists of relevant articles and reviews were hand searched to identify additional papers.

### *Study selection and data extraction*

Two reviewers (RT, AK) reviewed all abstracts independently. Any discrepancies on the potential relevance of the papers were resolved by consensus. We obtained full text copies of reviews that met the inclusion criteria.

We included reviews that assessed clinical characteristics, biochemical or ultrasound based variables as predictors or predictive tests for pre-eclampsia. We included reviews evaluating predictors in the first, second or third trimester. Case reports, case series, individual observational or randomised studies, narrative reviews, rapid reviews, editorials and poster abstracts were excluded. Two reviewers (RT, AK) independently extracted relevant data. We obtained data on year of publication, number of databases searched, number of studies included, number of pregnancies/women included, screening tests evaluated and the performance of the tests or degree of association reported with the predictors evaluated.

### *Definitions*

We accepted the authors' definition of pre-eclampsia and hypertensive disorders, and further collected data where it was reported discriminating between early onset pre-eclampsia (requiring delivery prior to 34 weeks' gestation), late onset (delivery after 34 weeks' gestation) or delivery at any time.

Clinical characteristics included signs, symptoms, past medical and obstetric history and environmental exposures elicited through maternal history or physical examination by the booking clinician at the first antenatal visit.

Biochemical tests included any measurement of molecules in biological fluids (eg serum and urine). Ultrasound tests included any characteristic identified on ultrasound examination of the pregnancy at any gestation.



We defined a predictor as a clinical characteristic, biochemical or ultrasound marker with the potential to predict the outcome of interest (pre-eclampsia). We defined a predictive model as a combination of predictors obtained through logistic regression analysis to discriminate between populations.

We defined a review as systematic if they included an explicit method for searching the literature, searched two or more databases, and if they provided well defined inclusion and exclusion criteria for studies.

#### *Quality assessment of the included reviews*

The rigour of the systematic review and risk of bias in the review findings were assessed using the AMSTAR tool and a modified approach to the QUIPS tool by two independent reviewers (RT, YP) <sup>(14–16)</sup> (Supplementary File 2). For the AMSTAR assessment we considered whether the reviewers undertook the following: 'a priori' study design, a comprehensive literature search, the status of publication (i.e. grey literature) used as an inclusion criterion, duplicate study selection and data extraction, provided details of the included and excluded studies, reported the characteristics of the included studies, assessed and documented the quality of the included studies, appropriately used the scientific quality of the studies in formulating conclusions, used appropriate methods to combine the findings of studies, assessed the likelihood of publication bias and reported any conflict of interest. We assessed the risk of bias reported in the included reviews according to the QUIPS domains that relate to the key methodological concerns of prognostic research. We considered whether the

reviewers had assessed the representativeness of the patient sample, the impact of study attrition, predictor and outcome measurement, important confounders and the quality of the statistical analysis in the primary studies.

Where this information was reported we considered whether the authors had made an assessment of the degree of associated risk of bias. For the studies of genetic factors we applied the Venice criteria<sup>(17)</sup> to assess the epidemiological credibility of the association based on the amount of evidence, replication and protection from bias in each study.

## RESULTS

### *Review identification*

Of the 2444 citations identified, 126 systematic reviews were included in our review. Figure 1 provides details of the review identification and selection process. A list of excluded studies is provided in Supplementary Table 1.

### *Quality Assessment using the AMSTAR tool*

Figure 2a provides the findings of the quality assessment of the included reviews using the AMSTAR tool. Less than a quarter of the included reviews followed a prospectively specified protocol (24/126, 19.1%). Most of the reviews did perform a comprehensive literature search (120/126, 95.2%) with the majority of reviewers searching more than 2 databases. (Figure 2a) The majority of reviews undertook duplicate study selection (111/126, 88.1%), provided the characteristics of the included studies (109/126, 86.5%), and assessed the likelihood of publication bias (80/126, 63.5%). However, only a quarter provided a list of the included and excluded studies (28/126, 22.2%). About half (71/126, 56.3%) of the reviews performed their literature search without language restriction. (Figure 2a)

Just over half assessed the quality of the included studies (67/126, 53.2%), and only a third took into account the quality of the studies in formulating their conclusions (38/126, 30.2%). The most commonly used tools for quality assessment were QUADAS (17/126, 13.5%) and the Newcastle-Ottawa Scale (NOS) (31/126, 24.6%) although neither are designed for predictive research.

None of the reviews published since 2013 used the Quality In Prognosis Studies (QUIPS) tool described in that year that is designed for predictive factor study quality assessment.<sup>(16)</sup>

Although only half of the reviews assessed the quality of the included studies, many of the primary studies were potentially methodologically biased. They were often retrospective or case-control in design and subject to bias. Examples include significant heterogeneity; failure of masking of those managing the pregnancy or the outcome assessors; nested case-control studies including only a subset of pre-eclampsia cases of the original cohort and failure of application of the screening test to all the eligible participants in cohort studies. Furthermore, the included primary studies had numerous limitations including poor reporting of summary statistics, variable cut-offs of continuous variables, variation in outcomes assessed and the adjustment factors used to calculate test performance.<sup>(18)</sup>

*Risk of bias in included reviews assessed using the modified QUIPS tool*

Figure 2b shows the findings of the assessment of included studies against the modified QUIPS tool. Only one study reported on all domains. Of the included reviews, 80/126 (63.5%) reported on participants and representativeness of the population and 56/80 (70%) reported a high or moderate risk of bias in this area in the primary studies. Study attrition was considered in 31/126 (24.6%) with 20/31 (64.5%) reporting a high or moderate risk of bias. Measurement of

predictors was evaluated in 101/126 (80.2%) reviews, with 63 (62.4%) describing a high or moderate risk of bias. Measurement of the outcome was well reported, considered in 109/126 (86.5%) of reviews, but 67/109 (61.4%) found a high risk of bias, most commonly related to heterogeneity or lack of clarity in the definition of the outcomes in primary studies. Confounding was considered in 84/126 (66.7%) and the review authors reported that 59/84 (70.2%) had a high or moderate risk of bias relating to insufficient or inappropriate adjustment for important covariables.

#### *Characteristics of the included reviews*

The included reviews reported on between 3 and 265 primary studies, with the majority including 10-50 primary studies and including up to 25,356,688 pregnancies in the largest review<sup>(19)</sup>. (Figure 3) Seventy-nine predictors were evaluated in the included reviews (Table 1). The majority of reviews (53.9%, 68/126) investigated biochemical or genetic tests for predicting pre-eclampsia while 36.5% (46/126) related to clinical characteristics. Ultrasound markers were reported in only 3.2% (4/126) and a combination of tests in 4.8% (6/126) of reviews (Figure 3). We identified two previous broad systematic reviews of primary studies investigating all screening tests for pre-eclampsia<sup>(20,21)</sup> from 2004 and 2008.

The most commonly reported clinical characteristics included BMI (n=9 reviews), age (n=2), parity (n=2), blood pressure (n=5) and 6 reviews reported on several clinical characteristics. For the biochemical markers, the following

were most commonly studied: PAPP-A (n=4), PlGF (n=5), sFlt-1 (n=3), PP13 (n=4). Over 30 additional markers were reviewed. The ultrasound tests included uterine artery dopplers (n=8) and placental vascularisation indices (n=1). Only two reviews <sup>(22,23)</sup> summarised the findings with an individual participant data (IPD) meta-analysis. The details of the included reviews (19–144) and key findings are shown in Table 2. Table 2a describes reviews of maternal characteristics, 2b relates to reviews of ultrasound markers, 2c to reviews including biomarkers singly or in combination with other factors and 2d to the genetic association studies.

The majority (67/126, 53.2%) of the included reviews reported odds ratio as a single measure of predictor association with pre-eclampsia rather than directly reporting predictive ability of the predictors investigated. (Table 2). Only 31/126 (24.6%) studies reported measures of predictive ability, with 19 reporting sensitivities and specificities, 6 area under the receiver operating curve (AUC) and 6 likelihood ratios (LR).

Twenty-one studies declared no funding had been received, while 32 studies lacked a formal statement regarding funding of the studies. Of the remaining studies, 14 (19.2%) declared multiple funding sources. The majority of studies (51/73, 69.8%) declaring their funding sources had been sponsored by national or regional governmental bodies (e.g. National Institute for Health Research (NIHR), National Institutes of Health (NIH), Canadian Institutes of Health Research (CIHR), Health technology Assessment (HTA), National

Health and Medical Research Council (NHMRC)). Nearly one quarter (21.9%) were funded through academic institutions, 19.2% by charitable bodies, 4.1% received funding from industry and 9.5% by international bodies, chiefly the World Health Organisation.

There was substantial variation in outcome reporting, including failure to report gestation at delivery and severity of pre-eclampsia. Despite the fact that there has been a transition from a severity-based to a temporal classification of pre-eclampsia <sup>(145)</sup>, only three reviews reported early-onset pre-eclampsia, probably because the outcome was infrequently reported in primary studies (Figure 2). Some studies combined pre-eclampsia with hypertensive disorders, which limited the comparisons between studies. Considerable heterogeneity was highlighted in many of the included reviews and precluded meta-analysis in 15.1% (19/126) reviews.

#### *Key individual predictors for pre-eclampsia*

The included reviews reported on over 90 predictors for pre-eclampsia. The findings of the included reviews are summarised in Table 2. For each predictor we applied the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach to prognostic studies<sup>(146)</sup> to assess the quality of the evidence supporting the associations found. (Supplementary table 3). The most robustly associated clinical, ultrasound and biochemical predictors included BMI, blood pressure, uterine artery Doppler findings and PLGF, sFit-1 and AFP. (Supplementary Table 4)

### *Clinical characteristics*

Maternal BMI was analysed as a continuous, binary or categorical variable, and was consistently considered to be a weak predictor of pre-eclampsia with a number of studies demonstrating a biological gradient, with increasing BMI increasing the risk of pre-eclampsia<sup>(98, 106)</sup>. Increased maternal blood pressure (BP), evaluated alone<sup>(19,132,136)</sup> or in combination with other predictors,<sup>(19, 61)</sup> in the first or second trimester, was also consistently associated with an increased risk of pre-eclampsia, but the measurement of blood pressure varied between studies.<sup>(16, 105, 108)</sup> In 2008 Cnossen et al compared the predictive ability of systolic and diastolic blood pressure (SBP and DBP) and mean arterial pressure (MAP) measured at booking and found that mean arterial pressure had a greater area under the curve (AUC 0.76, 95% CI 0.70-0.82) than either diastolic or systolic blood pressure for all pre-eclampsia.<sup>(132)</sup>

Other clinical characteristics evaluated that demonstrated a consistent association were donor oocyte use in assisted reproduction, sleep disordered breathing, polycystic ovary syndrome, periodontal disease and maternal infections.

### *Ultrasound markers*

First trimester uterine artery Doppler (UtAD) appears to have high specificity (92.1%, 95% CI: 88.6-94.6), but low sensitivity (47.8%, 95% CI: 39.0-56.8%) in predicting early onset pre-eclampsia.<sup>(25)</sup> The sensitivity of UtAD was even lower



for predicting any pre-eclampsia at only 26.4% (95% CI: 22.5-30.8%)(25). One review evaluated placental vascularisation indices (PVIs) measured at 3D ultrasound and found that PVI measured in the first trimester were found to be predictive of later pre-eclampsia with the most sensitive measure being the vascular flow index (VFI).<sup>(144)</sup> The authors reported an AUC for the prediction of early pre-eclampsia by the vascular flow index of 0.89 (95% CI: 0.78-1.00) and for any pre-eclampsia of 0.77 (95% CI: 0.69-0.84).<sup>(144)</sup>

### *Biochemical markers*

The biochemical screening markers were grouped according to their mechanism of action (Table 2). Of markers associated with angiogenesis, both PIGF and sFlt-1 were consistently associated with the risk of pre-eclampsia, with an odds ratio of 9.0 (95% CI 5.6–14.5) for PIGF tested before 30 weeks in one large study<sup>(49)</sup> and although another reported no significant association between first trimester PIGF and all pre-eclampsia OR 1.94 (95% CI 0.81 to 4.67) there was an association between first trimester PIGF and early onset PE (OR 3.41 ((95% CI 1.61-7.24).<sup>(96)</sup> For sFlt-1 odds ratios from 1.3 (95% CI 1.02-1.65) to 6.6 (3.1–13.7) were reported, with the association being stronger when tested later in pregnancy.<sup>(49,96)</sup> For a 5% false positive rate, PIGF and sFlt-1 had sensitivities of 32% and 26%, respectively.<sup>(49)</sup> Soluble endoglin (sEng) and VEGF were not as consistently found to be associated although at least one study reported that sEng had a sensitivity of 18% to detect PE for a 5% false positive rate.<sup>(49)</sup> Of the markers routinely tested during aneuploidy screening in

the first trimester, alpha feto protein (AFP) had the highest specificity of 96% (95% CI 94 to 98%) with a specificity of only 9% (95% CI 5-16%).<sup>(20)</sup>

A wide number of gene mutations were considered to be associated with the development of pre-eclampsia, but no single polymorphism was identified with a clinically useful predictive performance. (Table 2). The most frequently investigated genes were methylenetetrahydrofolate reductase (MTHFR) and endothelial nitric oxide synthase (eNOS), and a number of genes relating to elements of the renin-angiotensin-aldosterone system (RAAS) were investigated. The credibility of the association between the MTHFR C677T mutation and pre-eclampsia was generally weak and the association was not large. The credibility of association with mutations of the eNOS gene was moderate, but again this was not a large effect. These patterns do support an association between endothelial and RAAS function and pre-eclampsia, but are not at present useful for prediction of disease.

#### *Multivariable prediction models*

No screening marker, whether any of the clinical characteristics, ultrasound or biochemical markers, had both sensitivity and specificity greater than 90%.

Six reviews opted for an approach using combinations of predictive markers (Table 2)<sup>(22,85,88,97,99,100)</sup> and reported results for 52 individually described models while one group reported on an additional 70 models in groups labelled as 'simple' or 'specialised' based on the inclusion of ultrasound and biochemical

tests.<sup>(99)</sup> Of these studies, only one reported calibration statistics for the model described<sup>(22)</sup> and one found that of the 14 primary model development papers assessed, only 6 reported model calibration.<sup>(99)</sup> The remaining prediction modelling papers did not describe calibration of the models presented or assess calibration statistics in the primary studies reviewed. The detection rates (DR) of single markers (ADAM12, beta-hCG, inhibin A, activin A, PP13, PIGF and PAPP-A) for early-onset pre-eclampsia ranged from 22% to 83% for a fixed false positive rate of 10%.<sup>(88)</sup> These figures improve to between 38% and 100% when a combination of more than two markers was used.<sup>(88)</sup> The best results (DR 100%, 95% CI 69-100%) were achieved with the combination of three biochemical markers (Inhibin A, PIGF, PAPP-A), uterine artery Doppler and maternal characteristics.<sup>(88)</sup> For early-onset pre-eclampsia, a model containing only BMI was significantly improved by the addition of mean resistance index (RI) and bilateral notching, with the AUC increasing from 0.66 to 0.92 ( $P<0.001$ ). The addition of mean pulsatility index (PI) and bilateral notching improved the AUC from 0.62 to 0.95 ( $P<0.001$ ).<sup>(22)</sup> The sensitivity for early-onset pre-eclampsia using uterine artery Doppler PI, with mean arterial pressure was 83%,<sup>(85)</sup> but only 58.5% for late onset pre-eclampsia with the same markers. The improved performance of models containing Doppler or biomarkers is consistent with the finding of one study that adding ultrasound or biomarkers to models based on maternal characteristics alone led to a median gain of 18% in sensitivity.<sup>(99)</sup>

## DISCUSSION

Our review identified 126 systematic reviews on over 90 predictors for pre-eclampsia, although only around a quarter directly reported predictive ability. No test was found to have sensitivity and specificity above 90%. A high sensitivity and specificity are necessary to make screening more cost effective than a 'treat-all' policy in clinical practice.<sup>(20)</sup> BMI  $>34\text{kg/m}^2$ , AFP and bilateral uterine artery Doppler notching were reported with specificity of  $>90\%$  but with low sensitivities, rendering them unsuitable to safely categorise women as 'low risk'.<sup>(20)</sup> Individual predictors most correlated with pre-eclampsia were uterine artery Doppler indices and angiogenic biomarkers.<sup>(22,88,143)</sup> Prediction models combining maternal characteristics (particularly BP) with uterine artery Doppler and biomarkers were able to achieve sensitivity and specificity  $>80\%$ .<sup>(22,85,100)</sup>

### *Comparison with existing evidence*

Our search identified one prior 'umbrella' review on this topic<sup>(147)</sup> and two broad systematic reviews of primary studies for prediction of pre-eclampsia from the HTA in 2008<sup>(20)</sup> and the World Health Organisation (WHO) in 2004.<sup>(21)</sup> All three also identified BMI, uterine artery Doppler and AFP as high performing variables but were also limited by heterogeneity and inconsistent reporting in included primary studies.<sup>(20)</sup> A subsequently published review of systematic reviews of risk factors for pre-eclampsia, while not examining uterine artery Dopplers, also identified a number of maternal characteristics as important risk factors including obesity, primiparity and smoking status and additionally noted the strong association between assisted reproduction and pre-eclampsia that

should be considered in the development of new prediction tools.<sup>(148)</sup> Several of these studies reported evidence that infrequently studied predictors including kallikreinuria and fibronectin might offer high sensitivity in pre-eclampsia prediction and required further research. No new reviews including these predictors were identified in our search nearly ten years later although new variables, including cell free fetal DNA, can be added to the selection of variables that require further investigation. Previous reviews have also highlighted the need for development of multi-variable models. In this review we have identified over 50 models that have been reported in the last decade, but we also found none that had undergone external validation and could be recommended for routine practice.

#### *Strengths and weaknesses*

The strengths of this review include a thorough search strategy and critically evaluative approach. The analysis collates a wide variety of reviews representing the state of research in this field. The findings of the review are limited by the quality of included studies, compromised by limitations carried over from the primary studies and then the later conduct of the review analysis, especially where investigators did not address risks of bias particular to prediction research.

#### *Clinical and research implications*

Maternal characteristics at booking are currently used for screening by most guidelines.<sup>(5,149,150)</sup> An important characteristic, due to increasing prevalence, is

maternal obesity.<sup>(151,152)</sup> This review confirmed a plausible biological gradient associating maternal obesity with pre-eclampsia and observed that the inclusion of BMI improved the performance of several models.<sup>(22,88)</sup> It is likely that any clinically useful model would be improved by inclusion of a measurement of maternal obesity.

In seeking to improve on screening by maternal characteristics, many biomarkers were investigated. The angiogenic markers are most promising, particularly PIGF and sFlt-1.<sup>(49,61,84,95,96)</sup> Of the placental proteins, PP13 and PAPP-A were most consistently associated.<sup>(41,61,95,96,101)</sup> Large prospective studies using biomarkers are expensive and most data exists for markers routinely obtained during fetal anomaly screening. There is evidence in smaller studies for markers like fibronectin,<sup>(20,73)</sup> cell free fetal DNA<sup>(31,62)</sup> and urinary kallikrein<sup>(20,21)</sup> that requires further investigation.

This review further confirmed the screening performance of uterine artery Doppler in the first and second trimesters. Using a model combining systolic blood pressure, uterine artery PI and bilateral notching with BMI can achieve AUC 0.85 (95% CI: 0.67–1.00).<sup>(22)</sup> but this model is as yet still undergoing external validation, in the SPREE study comparing the National Institute for Health and Care Excellence (NICE) and Fetal Medicine Foundation (FMF) screening models.<sup>(153)</sup>

While in previous years the search has been for a single marker to predict pre-eclampsia, recognition of the heterogeneity of the disease phenotype and complexity of prediction has led to consensus that the best approach to pre-eclampsia screening is likely to be calculating individualised risk based on a combination of markers.<sup>(6)</sup> In this review we have identified key predictors that could be used in developing such a prediction model and propose a solution to address the problems of inconsistent reporting and heterogeneity that have consistently affected the ability of prior reviews to make recommendations on screening.<sup>(20,21,147)</sup> Since information on multiple predictors will be required, model development will optimally utilise individual level data which can facilitate analysis to identify the predictors that explain most of the variance of the full model. The aim of this approach, already established in cardiovascular prediction modelling,<sup>(154)</sup> is to develop a model well balanced between optimal performance and parsimony of included predictors leading to greatest ease of use in clinical practice.

Using individual patient data meta analysis for model development (IPD-MA) could additionally address poor reporting and heterogeneity in primary studies. While resource intensive and still subject to publication bias, IPD-MA is becoming the gold standard for predictive meta-analysis.<sup>(155)</sup> The advantages of IPD-MA over conventional meta-analysis include use of all available data; flexibility to combine data uniformly; the use of original data allowing analysis of continuous variables and comparison between datasets.<sup>(156)</sup> Moreover, it permits comparison of multivariable prediction strategies and the possibility of

time-to-event analysis, particularly relevant to pre-eclampsia where gestation is inextricably linked to maternal and fetal outcomes. <sup>(157)</sup>

Research priorities should include prospectively registered predictive studies of promising markers, with results for each marker alone and in combination with other tests and clear reporting of methods and timing of variable and outcome measurements. A particular focus should be high performance tests in the first trimester, when the benefits of intervention are greatest. IPD meta-analysis combining the most promising predictors can then be used to develop prediction models for external validation before introduction into clinical practice.

Predictive variables by themselves do not improve outcome; the subsequent preventive interventions do. Since it is not self-evident that a treatment has a stable effect in women with different profiles, predictive markers should be evaluated in studies that evaluate the impact of predictive strategies. <sup>(158)</sup> The ideal predictor not only predicts pre-eclampsia, but also predicts treatment modification, i.e. whether a treatment improves the outcome in a particular category of patients.

In order to conduct effective primary studies and analyses, consensus on outcomes is needed. Identification of a core outcome set for pre-eclampsia studies <sup>(159)</sup> is a key priority. Such an approach will enable us to move beyond repeating small, low quality prognostic factor studies to investigating the clinical impact of prediction model use in clinical practice.



**Funding**

BWM is supported by a NHMRC Practitioner Fellowship (GNT1082548)

**Conflict of interest**

BWM reports consultancy for ObsEva, Merck and Guerbet. ST is the CI of the NIHR funded IPD meta-analysis IPPIC to predict pre-eclampsia.

## REFERENCES

1. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, Harper A, Hulbert D, Lucas S, McClure J, Millward-Sadler H, Neilson J, Nelson-Piercy C, Norman J, O'Herlihy C, Oates M, Shakespeare J, de Swiet M, Williamson C, Beale V, Knight M, Lennox C, Miller A, Parmar D, Rogers J, Springett A. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. *BJOG*. 2011 Mar;118 Suppl:1–203.
2. Duley L. The Global Impact of Pre-eclampsia and Eclampsia. *Seminars in Perinatology*. 2009. p. 130–7.
3. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina F, Persico N, Jani J, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides K. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. *N Engl J Med*. Massachusetts Medical Society; 2017 Aug 17;377(7):613–22.
4. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest J, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. *Obstet Gynecol*. 2010 Aug;116(2 Pt 1):402–14.
5. Hypertension in pregnancy: diagnosis and management | NICE Clinical guideline 107. NICE; 2010
6. Poon LCY, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. *J Hum Hypertens*. 2010 Feb 11;24(2):104–10.
7. Vergheze L, Alam S, Beski S, Thuraishingham R, Barnes I, MacCallum P. Antenatal screening for pre-eclampsia: evaluation of the NICE and pre-eclampsia community guidelines. *J Obstet Gynaecol*. Informa Healthcare London; 2012 Feb 2;32(2):128–31.
8. O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, Carbone IF, Dutemeyer V, Fiolna M, Frick A, Karagiotis N, Mastrodima S, de Paco Matallana C, Papaioannou G, Pazos A, Plasencia W, Nicolaides K. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. *Ultrasound Obstet Gynecol*. 2017 Jun;49(6):756–60.
9. Kleinrouweler CE, Cheong-See F, Collins G, Kwee A, Thangaratinam S, Khan KS, Mol B, Pajkrt E, Moons K, Schuit E. Prognostic models in obstetrics: available, but far from applicable. *Am J Obstet Gynecol*. 2016;214(1):79–90.

10. Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC. How to write a Cochrane systematic review. *Nephrology*. 2010 Sep;15(6):617–24.
11. NHS Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York; 2009.
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, the STROBE initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. 2007 Oct 20;370(9596):1453–7.
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux P, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700
14. Shea BJ, Bouter LM, Peterson J, Boers M, Andersson N, Ortiz Z, Ramsay T, Bai A, Shukla VK, Grimshaw JM. External Validation of a Measurement Tool to Assess Systematic Reviews (AMSTAR). Gagnier J, editor. *PLoS One*. 2007 Dec 26;2(12):e1350.
15. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry D, Boers M. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol*. 2009 Oct;62(10):1013–20.
16. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing Bias in Studies of Prognostic Factors. *Ann Intern Med*. 2013 Feb 19;158(4):280.
17. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, Balding D, Chokkalingam A, Dolan SM, Flanders WD, Higgins JP, McCarthy MI, McDermott DH, Page GP, Rebbeck TR, Seminara D, Khoury MJ. Assessment of cumulative evidence on genetic associations: interim guidelines. *Int J Epidemiol*. Oxford University Press; 2008 Feb 1;37(1):120–32.
18. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. *Br J Cancer*. Nature Publishing Group; 2003 Apr 22;88(8):1191–8.
19. Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ*. 2016;353:i1753.
20. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, Roberts TE, Mol BW, van der Post JA, Leeflang MM, Barton PM, Hyde CJ, Gupta JK, Khan KS. Methods of prediction and prevention of pre-

- eclampsia. *Heal Technol Assess.* 2008;12(6):1–270.
21. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization Systematic Review of Screening Tests for Preeclampsia. *Obstet Gynecol.* 2004;104(6):1367–91.
  22. Kleinrouweler CE, Bossuyt PMM, Thilaganathan B, Vollebregt KC, Arenas Ramírez J, Ohkuchi A, Deurloo K, Macleod M, Diab A, Wolf H, van der Post J, Mol B, Pajkrt E. Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis. *Ultrasound Obstet Gynecol.* 2013;42(3):257–67.
  23. Schalekamp-Timmermans S, Arends L, Alsaker E, Chappell L, Hansson S, Harsem NK, Maya J, Jeyabalan A, Laivuori H, Lawlor D, Macdonald-Wallis C, Magnus P, Myers J, Olsen J, Poston L, Redman C, Staff AC, Villa P, Roberts JM, Steegers EAP. Fetal sex-specific differences in gestational age at delivery in pre-eclampsia: a meta-analysis. *Int J Epidemiol.* 2016;0(0).
  24. Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: A systematic review and meta-analysis of prospective cohort studies. *PLoS Med.* 2010;7(6).
  25. Velauthar L, Plana MN, Kalidindi M, Zamora J, Thilaganathan B, Illanes SE, Khan KS, Aquilina J, Thangaratnam, S. First-trimester uterine artery Doppler and adverse pregnancy outcome: A meta-analysis involving 55 974 women. *Ultrasound Obstet Gynecol.* 2014;43(5):500–7.
  26. Harvey NC, Holroyd C, Ntani G, Javaid K, Moon R, Cole Z, Tinati T, Godfrey K, Dennison E, Bishop NJ, Baird J, Cooper C. Vitamin D supplementation in pregnancy : A systematic review. *Heal Technol Assess.* 2014;18(45):1–190.
  27. Li X, Luo YL, Zhang QH, Mao C, Wang XW, Liu S, Chen Q. Methylenetetrahydrofolate reductase gene C677T, A1298C polymorphisms and pre-eclampsia risk: A meta-analysis. *Mol Biol Rep.* 2014;41(8):5435–48.
  28. Zafarmand MH, Nijdam M, Franx A, Grobbee DE, Bots ML. The angiotensinogen gene M235T polymorphism and development of preeclampsia / eclampsia : a meta-analysis and meta-regression of observational studies. 2006;1726–34.
  29. Zhu M, Zhang J, Nie S, Yan W. Associations of ACE I / D , AGT M235T gene polymorphisms with pregnancy induced hypertension in Chinese population : a meta-analysis. *J Assist Reprod Genet.* 2012;29:921–32.
  30. Zhu Q, Zhang L, Chen X, Zhou J, Liu J, Chen J. Association between zinc

- level and the risk of preeclampsia: a meta-analysis. *Arch Gynecol Obstet.* Springer Berlin Heidelberg; 2016;293(2):377–82.
31. Martin A, Krishna I, Martina B, Samuel A. Can the quantity of cell-free fetal DNA predict preeclampsia : a systematic review. *Prenat Diagn.* 2014;34:685–91.
  32. Qi H, Fraser WD, Luo Z, Audibert F, Wei S. Endothelial Nitric Oxide Synthase Gene Polymorphisms and Risk of Preeclampsia. *Am J Perinatol.* 2013;30:795–804.
  33. Ide M, Papapanou P. Epidemiology of association between maternal periodontal disease and adverse pregnancy outcomes - Systematic review. *J Clin Periodontol.* 2013;40(SUPPL. 14):S181–94.
  34. Wei J, Liu CX, Gong TT, Wu QJ WL. Cigarette smoking during pregnancy and preeclampsia risk: a systematic review and meta-analysis of prospective studies. *Oncotarget.* 2015;6(41):43667–78.
  35. Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O’Beirne M, Rabi DM. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. *BMJ.* 2013;346(mar26 4):f1169–f1169.
  36. Salihu H, De La Cruz C, Rahman S, August E. Does maternal obesity cause preeclampsia? A systematic review of the evidence. *Minerva Ginecol.* 2012;64:259–80.
  37. Song Q, Luo W, Zhang C. High serum iron level is associated with an increased risk of hypertensive disorders during pregnancy: a meta-analysis of observational studies. *Nutr Res. Elsevier Inc.;* 2015;35(12):1060–9.
  38. Chen H, Zhao G, Sun M, Wang H, Liu J, Gao W, Meng T. Endothelial Nitric Oxide Synthase Gene Polymorphisms (G894T, 4b/a and T-786C) and Preeclampsia: Meta-Analysis of 18 Case-Control Studies. *DNA Cell Biol.* 2012;31(6):1136–45.
  39. Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. *J Hypertens.* 2003;21(7):1221–8.
  40. Kosmas IP, Tatsioni A, Ioannidis JP. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. *J Hypertens.* 2004;22(9):1655–62.
  41. Morris RK, Bilagi A, Devani P, Kilby MD. Association of serum PAPP-A levels in first trimester with small-for-gestational-age and adverse pregnancy outcomes: systematic review and meta-analysis. *Prenat Diagn.* 2017;37:253–65.

42. Wang XM, Wu HY, Qiu XJ. Methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism and risk of preeclampsia: An updated meta-analysis based on 51 studies. *Arch Med Res. Elsevier Inc*; 2013;44(3):159–68.
43. Wu X, Yang K, Tang X, Sa Y, Zhou R, Liu J, Luo Y, Tang W. Folate metabolism gene polymorphisms MTHFR C677T and A1298C and risk for preeclampsia: a meta-analysis. *J Assist Reprod Genet.* 2015;32(5):797–805.
44. Yang W, Zhu Z, Wan J, Ding Y. Evaluation of association of maternal IL-10 polymorphisms with risk of preeclampsia by A meta-analysis Literature selection. *J Cell Mol Med.* 2014;18(12):2466–77.
45. Zhao L, Bracken MB, DeWan AT, Chen S. Association between the SERPINE1 (PAI-1) 4G/5G insertion/deletion promoter polymorphism (rs1799889) and pre-eclampsia: A systematic review and meta-analysis. *Mol Hum Reprod.* 2013;19(3):136–43.
46. Lau SY, Guild S, Barrett CJ, Chen Q, Mccowan L, Jordan V, Chamley L. Tumor Necrosis Factor-Alpha , Interleukin-6 , and Interleukin-10 Levels are Altered in Preeclampsia : A Systematic Review and Meta-Analysis. *Am J Reprod Immunol.* 2013;70:412–27.
47. Yu CK, Casas JP, Savvidou MD, Sahemey MK, Nicolaides KH, Hingorani AD. Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) and development of pre-eclampsia: a case-control study and a meta-analysis. *BMC Pregnancy Childbirth.* 2006;6:7.
48. Zhong WG, Wang Y, Zhu H, Zhao X. Meta analysis of angiotensin-converting enzyme I/D polymorphism as a risk factor for preeclampsia in Chinese women. *Genet Mol Res.* 2012;11(3):2268–76.
49. Kleinrouweler CE, Wiegerinck MMJ, Ris-Stalpers C, Bossuyt PMM, Van Der Post JAM, Von Dadelszen P, Mol B, Pakjrt E. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: A systematic review and meta-analysis. *BJOG An Int J Obstet Gynaecol.* 2012;119(7):778–87.
50. Pedersen M, Stayner L, Slama R, Sørensen M, Figueras F, Nieuwenhuijsen MJ, Raaschou-Nielsen O, Dadvand P. Ambient air pollution and pregnancy-induced hypertensive disorders: A systematic review and meta-analysis. *Hypertension.* 2014;64(3):494–500.
51. Wang X, Bai T, Liu S, Pan H, Wang B. Association between thrombophilia gene polymorphisms and preeclampsia: A meta-analysis. *PLoS One.* 2014;9(6).
52. Zeng F, Zhu S, Wong MC, Yang Z, Tang J, Li K, Su X. Associations between nitric oxide synthase 3 gene polymorphisms and preeclampsia

- risk: a meta-analysis. *Sci Rep*. Nature Publishing Group; 2016;6(1):23407.
53. Song GG, Kim J, Lee YH. Associations between vascular endothelial growth factor gene polymorphisms and pre-eclampsia susceptibility: a meta-analysis. *Immunol Invest*. 2013;42(8):749–62.
  54. Cnossen JS, de Ruyter-Hanhijärvi H, van der Post JAM, Mol BWJ, Khan KS, ter Riet G. Accuracy of serum uric acid determination in predicting pre-eclampsia: A systematic review. *Acta Obstet Gynecol Scand*. 2006;85(5):519–25.
  55. Yang Y, Su X, Xu W, Zhou R. Interleukin-18 and Interferon Gamma Levels in Preeclampsia: A Systematic Review and Meta-analysis. *Am J Reprod Immunol*. 2014;72(5):504–14.
  56. Anvar Z, Saadat I, Namavar-jahromi B, Saadat M. Genetic polymorphisms of Glutathione S-Transferase M1 (GSTM1) and T1 (GSTT1) and susceptibility to pre-eclampsia: a case-control study and a meta-analysis. *EXCLI J*. 2011;10:44–51.
  57. Lei J, Li Y, Zhang S, Wu Y, Wang P, Liu H. The Prognostic Role of Angiotensin II Type 1 Receptor Autoantibody in Non-Gravid Hypertension and Pre-eclampsia. *Medicine (Baltimore)*. 2016;95(17):e3494.
  58. Hyppönen E, Cavadino A, Fraser A. Vitamin D and Pre-Eclampsia : Original Data , Systematic Review and. *Ann Nutr Metab*. 2013;63:331–40.
  59. Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications : A systematic review and meta-analysis. *Thromb Res*. Elsevier Ltd; 2011;128(1):77–85.
  60. Cheng D, Hao Y, Zhou W, Ma Y. Vascular endothelial growth factor +936C/T, -634G/C, -2578C/A, and -1154G/A polymorphisms with risk of preeclampsia: A meta-analysis. *PLoS One*. 2013;8(11).
  61. Wu P, Van Den Berg C, Alfirevic Z, O'Brien S, Röthlisberger M, Baker PN, Kenny L, Kublickiene K, Duvekot J. Early pregnancy biomarkers in pre-eclampsia: A systematic review and meta-analysis. *Int J Mol Sci*. 2015;16(9):23035–56.
  62. Contro E, Bernabini D, Farina A. Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis. *Mol Diagn Ther*. Springer International Publishing; 2016;21(2):1–11.
  63. Shaik AP, Sultana A, Bammidi VK, Sampathirao K, Jamil K. A meta-analysis of eNOS and ACE gene polymorphisms and risk of pre-eclampsia in women. *J Obstet Gynaecol*. 2011;31(7):603–7.

64. Christesen HT, Falkenberg T, Lamont RF, Jørgensen JANS, Christesen HT, Christian H. The impact of vitamin D on pregnancy : a systematic review. *Acta Obstet Gynecol Scand*. 2012;91:1357–67.
65. Xie C, Yao MZ, Liu JB, Xiong LK. A meta-analysis of tumor necrosis factor-alpha, interleukin-6, and interleukin-10 in preeclampsia. *Cytokine*. 2011 56(3):550–9.
66. Lee YH, Kim JH, Song GG. Meta-analysis of associations between interleukin-10 polymorphisms and susceptibility to pre-eclampsia. *European Journal of Obstetrics Gynecology and Reproductive Biology*. Elsevier Ireland Ltd; 2014. p. 202–7.
67. Zhang L, Yang H, Qin H, Zhang K. Angiotensin II type I receptor A1166C polymorphism increases the risk of pregnancy hypertensive disorders: Evidence from a meta-analysis. *JRAAS*. 2014;15(2):131–8.
68. Pabalan N, Jarjanazi H, Sun C, Iversen AC. Meta-analysis of the human leukocyte antigen-G (HLA-G) 14 bp insertion/deletion polymorphism as a risk factor for preeclampsia. *Tissue Antigens*. 2015;86(3):186–94.
69. Dai B, Liu T, Zhang B, Zhang X, Wang Z. The polymorphism for endothelial nitric oxide synthase gene, the level of nitric oxide and the risk for pre-eclampsia: A meta-analysis. *Gene*. Elsevier B.V.; 2013;519(1):187–93.
70. Fan Y, Kang Y, Zhang M. A meta-analysis of copper level and risk of preeclampsia : evidence from 12 publications. *Biosci Rep*. 2016;36:e00370.
71. do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. *Obstet Gynecol*. 2010;116(6):1433–43.
72. Afshani N, Moustaqim-Barrette A, Biccard BM, Rodseth RN, Dyer RA. Utility of B-type natriuretic peptides in preeclampsia: A systematic review. *Int J Obstet Anesth*; 2013;22(2):96–103.
73. Leeflang MMG, Cnossen JS, van der Post JAM, Mol BWJ, Khan KS, ter Riet G. Accuracy of fibronectin tests for the prediction of pre-eclampsia: a systematic review. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2007 Jul 133(1):12–9.
74. Liu HQ, Wang YH, Wang LL, Hao M. Predictive Value of Free b-hCG Multiples of the Median for Women with Preeclampsia. *Gynecol Obstet Invest*. 2016; 81(2):137–47.
75. Chen Z, Xu F, Wei Y, Liu F, Qi H. Angiotensin converting enzyme insertion/deletion polymorphism and risk of pregnancy hypertensive disorders: a meta-analysis. *J Renin Angiotensin Aldosterone Syst*. 2012;13(1):184–95.



76. Zhao L, Dewan A, Bracken M. Association of maternal AGTR1 polymorphisms and preeclampsia: a systematic review and meta-analysis. *J Matern Neonatal Med.* 2012;25(12):2676–80.
77. Tabesh MM, Salehi-Abargouei A, Tabesh MM, Esmailzadeh A. Maternal Vitamin D Status and Risk of Pre-Eclampsia: A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab.* 2013 Aug;98(8):3165–73.
78. Bombell S, Guire M. Tumour necrosis factor (-308A) polymorphism in pre-eclampsia: Meta-analysis of 16 case-control studies. *Aust New Zeal J Obstet Gynaecol.* 2008;48(6):547–51.
79. Gupta S, Aziz N, Sekhon L, Agarwal R, Mansour G, Li J, Agarwal A. Lipid Peroxidation and Antioxidant Status in Preeclampsia. *Obstet Gynecol Surv.* 2009;64(11):750–9.
80. Wotherspoon AC, Young IS, McCance DR, Holmes VA. Evaluation of biomarkers for the prediction of pre-eclampsia in women with type 1 diabetes mellitus: A systematic review. *J Diabetes Complications.* Elsevier Inc.; 2016;30(5):958–66.
81. Ni S, Zhang Y, Deng Y, Gong Y, Huang J, Bai Y, Zhou R. AGT M235T polymorphism contributes to risk of preeclampsia: evidence from a meta-analysis. *J Renin-Angiotensin-Aldosterone Syst.* 2012;13(3):379–86.
82. Rebelo F, Schlüssel MM, Vaz JS, Franco-Sena AB, Pinto TJP, Bastos FI, Adegboye A, Kac G. C-reactive protein and later preeclampsia: systematic review and meta-analysis taking into account the weight status. *J Hypertens.* 2013 Jan;31(1):16–26.
83. Gallos ID, Sivakumar K, Kilby MD, Coomarasamy A, Thangaratinam S, Vatish M. Pre-eclampsia is associated with, and preceded by, hypertriglyceridaemia: A meta-analysis. *BJOG An Int J Obstet Gynaecol.* 2013;120(11):1321–32.
84. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M. Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors. *Obstet Gynecol.* 2007;109(1):168–80.
85. Zhu X, Wang J, Jiang R, Teng Y. Pulsatility index in combination with biomarkers or mean arterial pressure for the prediction of pre-eclampsia: Systematic literature review and meta-analysis. *Ann Med.* 2015;47(5):414–22.
86. Lin R, Lei Y, Yuan Z, Ju H, Li D. Angiotensinogen Gene M235T and T174M Polymorphisms and Susceptibility of Pre-Eclampsia: A Meta-Analysis. *Ann Hum Genet.* 2012;76(5):377–86.
87. Xia X, Chang W, Cao Y. Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to pre-eclampsia. *Hypertens Res.* 2012;35(12):1129–34.

88. Kuc S, Wortelboer EJ, Rijn BB Van, Franx A. First-Trimester Prediction of Preeclampsia : A Systematic Review. *Obstet Gynecol Surv.* 2011;66(4):225–39.
89. Li X, Shen L, Tan H. Polymorphisms and plasma level of transforming growth factor-beta 1 and risk for preeclampsia: A systematic review. *PLoS One.* 2014;9(5).
90. Morgan JA, Bombell S, McGuire W. Association of Plasminogen Activator Inhibitor-Type 1 (-675 4G/5G) Polymorphism with Pre-Eclampsia: Systematic Review. *PLoS One.* 2013;8(2).
91. Wang Z, Wang P, Liu H, He X, Zhang J, Yan H, Xu D, Wang B. Maternal adiposity as an independent risk factor for pre-eclampsia: A meta-analysis of prospective cohort studies. *Obes Rev.* 2013;14(6):508–21.
92. Xu T, Feng Y, Peng H, Guo D, Li T. Obstructive Sleep Apnea and the Risk of Perinatal Outcomes: A Meta-Analysis of Cohort Studies. *Sci Rep.* 2014;4:6982.
93. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: A meta-analysis. *Am J Epidemiol.* 2014;180(4):346–58.
94. Staines-Urias E, Paez MC, Doyle P, Dudbridge F, Serrano NC, Ioannidis JPA, Keating B, Hingorani AD, Casas JP. Genetic association studies in pre-eclampsia: Systematic meta-analyses and field synopsis. *Int J Epidemiol.* 2012;41(6):1764–75.
95. Zhong Y, Zhu F, Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. *BMC Pregnancy Childbirth.* BMC Pregnancy & Childbirth; 2015;15(1):191.
96. Allen RE, Rogozinska E, Cleverly K, Aquilina J, Thangaratinam S. Abnormal blood biomarkers in early pregnancy are associated with pre-eclampsia: a meta-analysis. *Eur J Obstet Gynecol Reprod Biol;* 2014;182:194–201.
97. Hui D, Okun N, Murphy K, Kingdom J, Uleryk E, Shah PS. Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review. *J Obstet Gynaecol Can.* 2012;34(2):142–53.
98. Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: Systematic review and metaanalysis. *Am J Obstet Gynecol.* 2008;198(1):7–22.
99. Al-Rubaie ZTA, Askie LM, Ray JG, Hudson HM, Lord SJ. The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that

- include specialised tests and with clinical guideline decision rules: a systematic review. *BJOG An Int J Obstet Gynaecol*. 2016;123(9):1441–52.
100. Giguère Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, Lafond J, Légaré F, Forest JC. Combining biochemical and ultrasonographic markers in predicting preeclampsia: A systematic review. *Clin Chem*. 2010;56(3):361–75.
  101. Schneuer FJ, Nassar N, Khambalia AZ, Tasevski V, Ashton AW, Morris JM, Roberts C. First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review. *Placenta*. 2012;33:735–40.
  102. Beltran AJ, Wu J, Laurent O. Associations of meteorology with adverse pregnancy outcomes: A systematic review of preeclampsia, preterm birth and birth weight. *Int J Environ Res Public Health*. 2013;11(1):91–172.
  103. Browne JL, Schrier VJMM, Grobbee DE, Peters SAE, Klipstein-grobusch K. HIV, Antiretroviral Therapy, and Hypertensive Disorders in Pregnancy : A Systematic Review and Meta-analysis. *J Acquir Immune Defic Syndr*. 2015;70(1):91–8.
  104. Tersigni C, Castellani R, De waure C, Fattorossi A, De Spirito M, Gasbarrini A, Scambia G, Di Simone N. Celiac disease and reproductive disorders: Meta-analysis of epidemiologic associations and potential pathogenic mechanisms. *Hum Reprod Update*. 2014;20(4):582–93.
  105. Schoenaker DAJM, Soedamah-Muthu SS, Mishra GD. The association between dietary factors and gestational hypertension and pre-eclampsia: a systematic review and meta-analysis of observational studies. *BMC Med*. 2014;12:157.
  106. González-Comadran M, Avila JU, Tascón AS, Jiménez R, Solà I, Brassesco M, Carreras R, Checa M. The impact of donor insemination on the risk of preeclampsia: A systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. 2014;182:160–6.
  107. Blazquez A, Garcia D, Rodriguez A, Vassena R, Figueras F, Vernaev V. Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis. *J Assist Reprod Genet. Journal of Assisted Reproduction and Genetics*; 2016;33(7):855–63.
  108. Ding X, Wu Y, Xu S, Zhang S-F, Jia X-M, Zhu R-P, Hao J, Tao F. A systematic review and quantitative assessment of sleep-disordered breathing during pregnancy and perinatal outcomes. *Sleep Breath*. 2014;18(4):703–13.
  109. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Reprod Biol Endocrinol*. 2013;11:56.

110. Cormick G, Betrán AP, Ciapponi A, Hall DR, Hofmeyr GJ. Inter-pregnancy interval and risk of recurrent pre-eclampsia: systematic review and meta-analysis. *Reprod Health. Reproductive Health*; 2016;13(1):83.
111. Alpoim PN, De Barros Pinheiro M, Junqueira DRG, Freitas LG, Das Graças Carvalho M, Fernandes APSM, Komatsuzaki F, Gomes K, Sant'Ana Dusse LM. Pre-eclampsia and ABO blood groups: a systematic review and meta-analysis. *Mol Biol Rep.* 2013 Mar;40(3):2253–61.
112. Dudding T, Heron J, Thakkestian A, Nurk E, Golding J, Pembrey M, Ring S, Attia J, Scott RJ. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: A genetic association study and meta-analysis. *J Thromb Haemost.* 2008;6(11):1868–75.
113. Xu Y, Ren L, Zhai S, Luo X, Hong T, Liu R, Ran L, Zhang Y. Association Between Isolated Single Umbilical Artery and Perinatal Outcomes: A Meta-Analysis. *Med Sci Monit.* 2016;22:1451–9.
114. Li H, Huang S, Zhang J, Meng Q, Wang H. Association between intrauterine device use and preeclampsia risk : a meta-analysis of observational studies. *Int J Clin Exp Med.* 2016;9(11):20605–14.
115. Masoudian P, Nasr A, Nanassy J De, Demellawy D El. Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension : a systematic review and metaanalysis. *Am J Obstet Gynecol.* Elsevier Inc.; 2016;214(3):328–39.
116. Aune D, Saugstad OD, Henriksen T, Tonstad S. Physical activity and the risk of preeclampsia: a systematic review and meta-analysis. *Epidemiology.* 2014;25(3):331–43.
117. Kangatharan C, Labram S, Bhattacharya S. Interpregnancy interval following miscarriage and adverse pregnancy outcomes: systematic review and meta-analysis. *Hum Reprod Update.* 2016;23(2):221–31.
118. Wolf HT, Owe KM, Juhl M, Hegaard HK. Leisure time physical activity and the risk of pre-eclampsia: a systematic review. *Matern Child Health J.* 2014 May;18(4):899–910.
119. Basaran A, Basaran M, Topatan B, Martin Jr. JN. Effect of chorionic villus sampling on the occurrence of preeclampsia and gestational hypertension: An updated systematic review and meta-analysis. *J Turkish Ger Gynecol Assoc.* 2016;17(2):65–72.
120. Franchini M, Mengoli C, Lippi G. Relationship between ABO blood group and pregnancy complications: a systematic literature analysis. *Blood Transfus.* 2016;14:441–8.
121. Huang X, Wang J, Liu J, Hua L, Zhang D, Hu T, Ge Z. Maternal periodontal disease and risk of preeclampsia: a meta-analysis. *J Huazhong Univ Sci Technolog Med Sci.* 2014;34(5):729–35.

122. Zhang S, Ding Z, Liu H, Chen Z, Wu J, Zhang Y, Yu Y. Association between mental stress and gestational hypertension/preeclampsia: A meta-analysis. *Obstet Gynecol Surv.* 2013;68(12):825–34.
123. Zhang G, Zhao J, Yi J, Luan Y, Wang Q. Association Between Gene Polymorphisms on Chromosome 1 and Susceptibility to Pre-Eclampsia: An Updated Meta-Analysis. *Med Sci Monit.* 2016;22:2202–14.
124. Weissgerber T, Milic N, Milin-Lazovic J, Garovic V. Impaired flow-mediated dilation before, during and after pre-eclampsia: a systematic review and meta-analysis. *Hypertension.* 2016;67(2):415–23.
125. O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. *Epidemiology.* 2003;14(3):368–74.
126. Adams JW, Watts DH, Phelps BR. A systematic review of the effect of HIV infection and antiretroviral therapy on the risk of pre-eclampsia. *Int J Gynecol Obstet. International Federation of Gynecology and Obstetrics;* 2016;133(1):17–21.
127. Kunnen A, van Doormaal JJ, Abbas F, Aarnoudse JG, van Pampus MG, Faas MM. Periodontal disease and pre-eclampsia: a systematic review. *J Clin Periodontol.* 2010 Dec;37(12):1075–87.
128. Sgolastra F, Petrucci A, Severino M, Gatto R, Monaco A. Relationship between Periodontitis and Pre-Eclampsia: A Meta-Analysis. *PLoS One.* 2013;8(8):e71387.
129. Rustveld LO, Kelsey SF, Sharma R. Association between maternal infections and preeclampsia: A systematic review of epidemiologic studies. *Matern Child Health J.* 2008;12(2):223–42.
130. Poorolajal J, Jenabi E. The association between body mass index and preeclampsia: a meta-analysis. *J Matern Fetal Neonatal Med.* 2016;29(22):3670–6.
131. Yu H, Chen H, Rao D-P, Gong J. Association between polycystic ovary syndrome and the risk of pregnancy complications. *Medicine (Baltimore).* 2016;95(51):e4863.
132. Cnossen JS, Vollebregt KC, Vrieze N d, ter Riet G, Mol BWJ, Franx A, Khan K, van der Post JAM. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. *BMJ.* 2008;336(7653):1117–20.
133. Cnossen JS, Leeflang MMG, De Haan EEM, Mol BWJ, Van Der Post JAM, Khan KS, ter Riet G. Accuracy of body mass index in predicting pre-eclampsia: Bivariate meta-analysis. *BJOG: An International Journal of Obstetrics and Gynaecology.* 2007. p. 1477–85.
134. Morris RK, Cnossen JS, Langejans M, Robson SC, Kleijnen J, ter Riet G,

- Mol B, van der Post JAM, Khan KS. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. *BMC Pregnancy Childbirth*. 2008 Aug 4;8:33.
135. Wei B, Chen Y, Yu L, Wu B. Periodontal Disease and Risk of Preeclampsia: A Meta-Analysis of Observational Studies. *PLoS One*. 2013;8(8):e70901.
136. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *BMJ*. 2005;330(7491):565–0.
137. Calvert C, Ronsmans C. HIV and the Risk of Direct Obstetric Complications: A Systematic Review and Meta-Analysis. *PLoS One*. 2013;8(10).
138. Hu H, Ha S, Roth J, Kearney G, Talbott EO, Xu X. Ambient air pollution and hypertensive disorders of pregnancy: A systematic review and meta-analysis. *Atmospheric Environment*; 2014. p. 336–45.
139. Jevé YB, Potdar N, Opoku A, Khare M. Donor oocyte conception and pregnancy complications: a systematic review and meta-analysis. *BJOG* 2016;123(9):1471–80.
140. Palmer KT, Bonzini M, Harris EC, Linaker C, Bonde JP. Work activities and risk of prematurity, low birth weight and pre-eclampsia: an updated review with meta-analysis. *Occup Environ Med*. 2013;70(4):213–22.
141. Huang Q, Chen J, Zhong M, Hang L, Wei S, Yu Y. Chronic Hepatitis B Infection is Associated with Decreased Risk of Preeclampsia : A Meta-Analysis of Observational Studies. *Cell Physiol Biochem*. 2016;38:1860–8.
142. Thomopoulos C, Tsioufis C, Michalopoulou H, Makris T, Papademetriou V, Stefanadis C. Assisted reproductive technology and pregnancy-related hypertensive complications: a systematic review. *J Hum Hypertens*. Nature Publishing Group; 2013;27(3):148–57.
143. Cnossen JS, Morris RK, ter Riet G, Mol BWJ, van der Post JAM, Coomarasamy A, Zwiderman A, Robson S, Bindels P, Kleijnen J, Khan KS. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. *CMAJ*. 2008 Mar 11;178(6):701–11.
144. Eastwood KA, Patterson C, Hunter AJ, McCance DR, Young IS, Holmes VA. Evaluation of the predictive value of placental vascularisation indices derived from 3-Dimensional power Doppler whole placental volume scanning for prediction of pre-eclampsia: A systematic review and meta-analysis. *Placenta*; 2017;51:89–97.

145. von Dadelszen P, Magee LA, Roberts JM. Subclassification of Preeclampsia. *Hypertens Pregnancy*. 2003 Jan 7;22(2):143–8.
146. Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams K, Kyzas PA, Malats N, Briggs A, Schroter S, Altman G, Hemingway Harry, for the PROGRESS group. Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. *PLoS Med*. Public Library of Science; 2013 Feb 5;10(2):e1001380.
147. Cnossen JS, ter Riet G, Mol BW, Van Der Post JA, Leeftang MM, Meads CA, Hyde C, Khan KS. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. *Acta Obstet Gynecol Scand*. 2009;88(7):758–65.
148. Giannakou K, Evangelou E, Papatheodorou SI. Genetic and non-genetic risk factors for pre-eclampsia: umbrella review of systematic reviews and meta-analyses of observational studies. *Ultrasound Obstet Gynecol*. Wiley-Blackwell; 2018 Jun 1;51(6):720–30.
149. American College of Obstetricians and Gynecologists. Hypertension in Pregnancy Task Force. Hypertension in Pregnancy. 2013.
150. SOGC. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary. *SOGC Clin Pract Guidel* 307. 2014;
151. Haslam DW, James WPT. Obesity. 2005 Oct 1;366(9492):1197–209.
152. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore S, Tobias G, Anton-Culver H, Beane Freeman L, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee I, Linet M, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett W, Thun MJ. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med*. 2010 Dec 2;363(23):2211–9.
153. Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LCY. Protocol for the prospective validation study: ‘Screening programme for pre-eclampsia’ (SPREE). *Ultrasound Obstet Gynecol*. 2017 Aug;50(2):175–9.
154. Airaksinen J, Jokela M, Virtanen M, Oksanen T, Pentti J, Vahtera J, Koskenvuo M, Kawachi I, Batty G, Kivimaki M. Development and validation of a risk prediction model for work disability: multicohort study. *Sci Rep*. Nature Publishing Group; 2017 Dec 19;7(1):13578.
155. Abo-Zaid G, Sauerbrei W, Riley RD. Individual participant data meta-analysis of prognostic factor studies: state of the art? *BMC Med Res Methodol*. BioMed Central; 2012 Dec 24;12(1):56.
156. Khan KS, Bachmann LM, ter Riet G. Systematic reviews with individual

patient data meta-analysis to evaluate diagnostic tests. *Eur J Obstet Gynecol Reprod Biol.* 2003 Jun 10;108(2):121–5.

157. Broeze KA, Opmeer BC, van der Veen F, Bossuyt PM, Bhattacharya S, Mol BWJ. Individual patient data meta-analysis: a promising approach for evidence synthesis in reproductive medicine. *Hum Reprod Update.* 2010 Nov 1;16(6):561–7.
158. Steyerberg EW. *Clinical Prediction Models.* New York, NY: Springer New York; 2009.
159. Khan K. The CROWN initiative: Journal editors invite researchers to develop core outcomes in women's health. *J Obstet Gynaecol Res.* 2016 Jun;42(6):599–601.



## Figure Legends

Figure 1 Flow chart illustrating identification of studies included in this systematic review. \*some studies reported on markers in more than one category

Figure 2a - AMSTAR assessment of included studies

Figure 2b - QUIPS assessment of included studies

Figure 3. Summary of characteristics of included studies

Table 1. Screening markers for pre-eclampsia investigated in systematic reviews

<p><b>Maternal characteristics</b></p> <ul style="list-style-type: none"> <li>• Age</li> <li>• Parity</li> <li>• Body mass index</li> <li>• Previous pre-eclampsia</li> <li>• Family history of pre-eclampsia</li> <li>• Multiple pregnancy</li> <li>• Pre-existing medical conditions (such as diabetes, antiphospholipid syndrome)</li> <li>• Interval between pregnancies</li> <li>• Common occupational exposures (prolonged working hours, shift work, lifting, standing and heavy physical workload)</li> <li>• Infection (bacterial/viral/other)</li> <li>• Periodontal disease</li> <li>• Mental stress</li> <li>• Polycystic ovary syndrome</li> <li>• ABO blood group status</li> <li>• Ambient air pollution</li> <li>• Coeliac disease</li> <li>• Dietary factors (energy, nutrients, foods or overall dietary patterns, alone or in combination with dietary supplements)</li> <li>• Cigarette smoking</li> <li>• Donor insemination/donor oocyte use</li> <li>• Physical activity</li> <li>• Intra-uterine device (IUD) use</li> <li>• Meteorological conditions</li> <li>• Obstructive sleep apnoea</li> <li>• Chorionic villus sampling</li> <li>• Past obstetric history (previous pre-eclampsia, stillbirth, growth restriction or abruption)</li> <li>• Flow mediated dilatation (FMD)</li> <li>• Blood pressure</li> </ul>
<p><b>Ultrasound markers</b></p> <ul style="list-style-type: none"> <li>• Uterine artery Doppler</li> <li>• Placental vascularisation indices</li> </ul>
<p><b>Biochemical markers</b></p> <p><i>Angiogenic/antiangiogenic markers</i></p> <ul style="list-style-type: none"> <li>• Placental growth factor (PIGF) (blood and urine)</li> <li>• Soluble fms-like tyrosine kinase one (sFlt1)</li> <li>• Soluble endoglin (sEng)</li> <li>• Vascular endothelial growth factor (VEGF)</li> <li>• Transforming Growth Factor-Beta 1 (TGFb1)</li> </ul> <p><i>Inflammatory markers</i></p> <ul style="list-style-type: none"> <li>• Tumour Necrosis Factor alpha (TNF <math>\alpha</math>)</li> <li>• C-reactive protein (CRP)</li> <li>• Interleukin-6, -10 and -19</li> </ul>

- Interferon (IFN) gamma
- P-selectin
- Pentraxin

*Markers of lipid metabolism and oxidative stress*

- Serum malondialdehyde (MDA), thiobarbituric acid-reactive substances (TBARS), superoxide dismutase (SOD)
- Hypertriglyceridaemia
- Hyperlipidaemia

*Cardiac markers*

- B-type natriuretic peptides (BNP)

*Markers of renal dysfunction*

- Urinary protein to creatinine ratio (PCR)
- Urinary calcium excretion, urinary calcium to creatinine ratio
- Urinary proteinuria (24-hour/spot tests for total proteinuria, albuminuria, microalbuminuria, albumin to creatinine ratio, kallikrein, SDS-PAGE proteins)

*Prothrombotic markers*

- Factor V Leiden gene mutation
- Prothrombin gene mutation (PGM)
- Anticardiolipin Antibodies (ACA)
- Antiphospholipid antibodies (APLA)
- D-dimer

*Markers of fetoplacental unit endocrine dysfunction*

- Human chorionic gonadotrophin (HCG)
- Alpha-Fetoprotein (AFP)
- Inhibin A
- Activin A
- Pregnancy-associated plasma protein A (PAPP-A)
- Placental protein 13 (PP13)
- Oestriol
- Metalloproteinase domain 12 (ADAM12)
- Corticotropin releasing hormone
- Serum uric acid
- Vitamin D

*Others*

- Fibronectin (maternal blood)
- Vitamins and mineral levels (Vitamins C and E, copper, iron and zinc levels)
- Free fetal DNA

**Genetic associations**

- Methyltetrahydrofolate reductase (MTHFR) polymorphisms
- Glutathione S transferase polymorphisms
- Endothelial nitric oxide synthase polymorphisms
- Plasminogen activator inhibitor 1 (PAI-1) polymorphism
- VEGF polymorphisms
- TGFb1 polymorphisms
- IL-10 polymorphisms
- TNF alpha polymorphisms
- HLA-G 14bp I/D polymorphisms
- AGT II receptor polymorphisms

- ACE I/D polymorphisms
- AGT polymorphisms
- Prothrombin gene polymorphisms

Table 2a. Predictive ability of maternal characteristics for pre to eclampsia							
Author Year	No. of primary studies	No. of databases searched	No. of women	Risk factors evaluated	Reported measure of test performance	Review pooled results (95% confidence intervals)	Outcome reported
Maternal characteristics (clinical assessment)							
Cnossen 2007	36	4	1699073	BMI or obesity	Sensitivity and Specificity	BMI >25 Sn 47% (33 to 61) Sp 73% (64 to 83%)	All PE
						BMI >35 Sn 21% (12 to 31) Sp 92% (89 to 95)	
O'Brien 2003	13	2	1390226		RR	0.54% (0.27 to 0.8) increase per 1 kg/m <sup>2</sup> increase in BMI	All PE
Wang 2013*	29	N/A	1980761		RR	Overweight RR 1.58 (1.44 to 1.72)	All PE
						Obese RR 2.68 (2.39 to 3.01)	
						Severely obese RR 3.12 (2.24 to 4.36)	
Salihi 2012	14	2	774366		Narrative		All PE
Poorolajal 2016	23	4	1387599		OR	BMI 25 to 30 OR 1.73 (1.59 to 1.87)	All PE
						BMI> 30 OR 3.15 (2.96 to 3.35)	
Weissgerber 2016	12	3	1103	Flow mediated dilation	SMD	-0.78 ( -1.19 to -0.37)	All PE

Alpoim 2013*	2	4	1875	ABO blood group status	OR	AB group OR 2.42 (1.63 to 3.58)	Early-onset PE
						A group OR 0.86 (0.69-1.06)	
						B group OR 1.1 (0.67-1.8)	
						O group OR 0.89 (0.71-1.11)	
Franchini 2016	9	2	697285		OR	O group OR 0.77 (0.67 to 0.88)	All PE
						AB group OR 1.94 (1.2 to 3.13)	
						A group OR 1.78 (1.04 to 3.07)	
Conde Agudelo 2008	5	7	8811336	Maternal infections (UTI, periodontal disease, HIV, malaria, Hepatitis)	OR	UTI OR 1.57 (1.45 to 1.7)	All PE
						Periodontal disease OR 1.76 (1.43 to 2.18)	
						<i>Chlamydia pneumoniae</i> , <i>H. pylori</i> , CMV, HIV, malaria, HSV, BV, <i>mycoplasma hominis</i> : not associated	
Rustveld 2008	16	3	20586		OR	Any infection OR 2.08 (1.63 to 2.65)	All PE
Basaran 2016	6	1	47599	Chorionic villus sampling	OR	0.83 (0.42 to 1.67)	All PE
Sgolastra 2013*	15	8	5023	Periodontal disease	OR	2.17 (1.38 to 3.41)	All PE
Kunnen 2010*	15	3	Not specified		Narrative		Early-onset PE
Wei 2013	15	2	9192		OR	2.79 (2.01 to 3.01)	All PE
Ide 2013	5	4	5024		OR	1.61 (1.36 to 1.92)	All PE
Huang 2014	11	2	3916		OR	3.69 (2.58 to 5.27)	All PE
Huang 2016	11	2	11566	Hepatitis B	OR	0.77 (0.65 to 0.90)	All PE
Calvert 2013	9	4	14971	HIV	OR	1.04 (0.60 to 1.79)	All PE
Adams 2016	13	4	21200		Narrative		All PE
Browne 2015	16	3	8817384		OR	1.01 (0.87 to 1.18)	All PE
Zhang 2013	13	5	668005	Mental stress	OR	1.49 (1.27 to 1.74)	All PE
Yu 2016	25	3	Not specified	Polycystic ovarian syndrome	OR	2.79 (2.29 to 3.38)	All PE
Qin 2013	15	3	1198662		OR	2.17 (1.91 to 2.46)	All PE

<b>Pedersen 2014</b>	4 (PM <sub>2.5</sub> )	2	127798 (PM <sub>2.5</sub> )	Ambient air pollution	OR	PM <sub>2.5</sub> OR 1.31 (1.14 to 1.5)	All PE
	4 (NO <sub>2</sub> )		120042 (NO <sub>2</sub> )			NO <sub>2</sub> OR 1.07 (1.02 to 1.13)	
	3 (NO <sub>x</sub> )		170694 (NO <sub>x</sub> )			NO <sub>x</sub> OR 1.05 (0.98 to 1.13)	
	3 (PM <sub>10</sub> )		50109 (PM <sub>10</sub> )			PM <sub>10</sub> OR 1.03 (0.91, 1.17)	
	3 (CO)		95853 (CO)			CO OR 0.95 (0.86 to 1.05)	
	3 (Traffic)		NA (traffic)			Traffic OR 1.03 (1.01 to 1.06)	
	3 (O <sub>3</sub> )		115891 (O <sub>3</sub> )			O <sub>3</sub> OR 1.09 (0.98 to 1.21)	
<b>Hu 2014</b>	6	5	282117		OR	NO <sub>2</sub> OR 1.1 per 10 ppb (1.03 to 1.17)	All PE
						PM <sub>10</sub> OR 0.98 per 10 ppb (0.91 to 1.05)	
						PM <sub>2.5</sub> OR 1.1 (0.96 to 1.26)	
<b>Tersigni 2014</b>	2	2	9436	Celiac disease	OR	1.41 (0.73 to 2.71)	All PE
<b>Wei 2015</b>	17	2	1800000	Cigarette smoking	RR	0.67 (0.6 to 0.75)	All PE
<b>Cnossen 2008</b>	34	4	60599	Blood pressure	AUC	MAP 0.76 (0.70 to 0.82)	All PE
						sBP 0.68 (0.64 to 0.72)	
						dBp 0.66 (0.59 to 0.72)	
<b>Wolf 2014*</b>	11	2	170679	Leisure time physical activity	Narrative		All PE
<b>Aune 2014</b>	15	3	185121		RR	0.65 (0.47 to 0.89)	All PE
<b>Gonzalez-Comadran 2014</b>	7	2	10898	Donor insemination	OR	1.63 (1.36 to 1.95)	All PE
<b>Blazquez 2016</b>	11	3	26302	Donor oocyte use	OR	3.05 (2.48-3.74)	All PE
<b>Masoudian 2016</b>	4	4	16553		OR	4.34 (3.1 to 6.06)	All PE
<b>Jeve 2016</b>	10	7	11539		OR	2.90 (1.98-4.24)	All PE
<b>Thomopoulos 2017</b>	7	2	225279	Assisted reproductive technology use	RR	Ovulation induction RR 1.48 (1.12 to 1.96)	All PE

						IVF/ICSI RR 1.65 (1.53 to 1.77)	
Li 2016	3	4	167680	Intra-uterine device use	RR	0.74 (0.61-0.90)	All PE
Schalekamp-Timmermans 2016	11	n/a	219575	Female fetal gender	OR	1.36 (1.17-1.5)	Early-onset PE
Cormick 2016	2	3	26174	Inter-pregnancy interval	OR	<2 years 1.01 (0.95 to 1.07)	All PE
						>2 years 1.1 (1.02-1.19)	
Kangatharan 2016	5	4	284899		OR	< 6 months 0.95 (0.88 to 1.02)	All PE
Ding 2013	12	3	9962	Sleep disordered breathing	OR	2.19 (1.71 to 2.8)	All PE
Xu 2014	5	5	977		RR	1.96 (1.34 to 2.86)	All PE
Palmer 2013*	11	2	N/A	Occupational exposures	Narrative		All PE
Schoenaker 2014	2	38	271472	Dietary factors	WMD	Kcal/day WMD 46 ( -13.8 to 106.23)	All PE
						Mg intake WMD -9.75 mg/day ( -21.26 to 1.76)	
						Ca intake WMD -56.32 mg/day (-120.69 to 8.06)	
Beltran 2014	2	24	N/A	Meteorological factors	RR	Birth in Spring v Summer RR 1.05 (0.87 to 1.27)	All PE



**Table 2b. Ability of ultrasound markers to predict pre-eclampsia**

Author Year	No. of primary studies	No. of databases searched	No. of women	Risk factors evaluated	Reported measure of test performance	Review pooled results (95% confidence intervals)	Outcome reported
Velauthar 2014*	18	3	55974	First trimester uterine artery doppler	Sensitivity and Specificity	Sensitivity 47.8% (39 to 56.8%) Specificity 92.1% (88.6 to 94.6%)	Early-onset PE
						Sensitivity 26.4% (22.5 to 30.8%) Specificity 93.4% (90.4 to 95.5%)	All PE
Cnossen 2008	3	4	4966	Second trimester uterine artery doppler	Sensitivity and Specificity	PI: Sens 25% (20-31) Spec 95% (95-96%)	All PE
Cnossen 2008	7	4	38230		Sensitivity and Specificity	PI: Sens 42% (25-58%) Spec 91% (86-96%),	All PE
	17	4	36969		Sensitivity and Specificity	Bilateral notching: Sens 43% (26-60%), Spec 93% (90-97%)	All PE
Eastwood 2017	3	4	1865	Placental vascularisation indices in first trimester	MD	VI: MD -2.93 ( -5.84 to -0.01)	All PE
						FI: MD -2.83 (3.97 to -1.69)	
						VFI: MD -0.93 (-1.6 to -0.25)	
Xu 2016	3	3	65226	Single fetal umbilical artery	OR	0.820 (0.56 to 1.21)	All PE

**Table 2c. Ability of biomarkers to predict pre-eclampsia**

Author Year	No. of primary studies	No. of databases searched	No. of women	Risk factors evaluated	Reported measure of test performance	Review pooled results (95% confidence intervals)	Outcome reported
Angiogenic and antiangiogenic markers							
Widmer 2007	10	5	1173	sFlt-1	Narrative		Early-onset PE
Kleinrouweler 2012	19	2	5337		OR	6.6 (3.1 to 13.7)	Early-onset PE
Allen 2014	4	3	1045		OR	1.3 (1.02 to 1.65)	All PE
	3		569		OR	1.2 (0.33 to 4.41)	Early-onset PE
Widmer 2007	14	5	2045	PIGF	Narrative		Early-onset PE
Kleinrouweler 2012	15	2	10612		OR	9.0 (5.6 to 14.5)	All PE
Allen 2014	4	3	987		OR	1.94 (0.81 to 4.67)	All PE
			1590		OR	3.41 (1.61 to 7.24)	Early-onset PE
Wu 2015	8	4	Not specified		Sensitivity and specificity	SN 65% (63-67%), SP 89% (89-89%)	All PE
	3		Not specified		Sensitivity and specificity	SN 37% (27-48%) SP 79% (78-81%)	Early-onset PE
Zhong 2015	2	4	8424		LR	LR+ 4.01 (3.74 to 4.28), LR- 0.67 (0.64 to 0.69)	All PE
	6				LR	LR+ 6.05 (5.55 to 6.55), LR- 0.48 (0.43 to 0.52)	Early-onset PE
Kleinrouweler 2012	4	2	2143	sEng	OR	4.2 (2.4 to 7.2)	All PE
Allen 2014	2	3	854		OR	1.23 (0.79 to 1.94)	All PE

Allen 2014	2	2	2143		OR	18.54 (8.38 to 41.02)	Early-onset PE	
Kleinrouweler 2012*	3		265	VEGF	SMD	-1.25 ( -2.73 to -0.23)	All PE	
Markers of fetal placental unit function								
Schneuer 2012*	4	3	6161	PP13	Sensitivity	All PE: 24% for 5% FPR Early PE: 45% for 5% FPR	Early to onset PE	
Allen 2014	4	3	3948		OR	4.42 (2.86 to 6.84)	All PE	
	3	3	3984		OR	7.51 (2.5 TO 22.53)	Early-onset PE	
Wu 2015	9	4	n/s		Sensitivity and specificity	All PE SN 37% (33-41%) SP 89% (89-89%) Early PE SN 59% (48-69%) SP 92% (91-93%)		All PE
Zhong 2015	6	3	60786			LR	Early PE LR+ 4.2 (3.69 to 4.71) LR- 0.6 (0.53 to 0.66) All PE LR+ 2.69 (2.05 to 3.32) LR- 0.6 (0.53 to 0.66)	
Morris 2017	8	4	132076	PAPP-A	OR	<5 <sup>th</sup> centile OR 1.94 (1.63 to 2.3)	All PE	
Allen 2014	12	3	56695		OR	2.05 (1.62 to 2.59)	All PE	
	5	3	9713		OR	4.84 (2.49 to 9.41)	Early-onset PE	
Wu 2015	14	4	n/s		Sensitivity and specificity	All PE SN 30% (29-32%) SP 92% (92-92%) Early PE SN 26% (19-34%) SP 90% (89-90%) Late PE SN 19% (14024%) SP 89% (89-90%)		All and early PE
Zhong 2015	16	3	385634		LR	Early LR+ 2.98 (2.55 to 3.41) LR- 0.7 (0.65 to 0.74) Late LR+ 1.58 (0.86 to 2.31), LR- 0.87 (0.74 to 1.00)		Early and late PE
Wu 2015	14	4	n/s	Inhibin A	Sensitivity and specificity	SN 32% (25-39%) SP 90% (89-91%)	All PE	

Allen 2014	3	3	1152		OR	3.57 (1.68-7.61)	All PE
Liu 2016	12	7	8935	bHCG	SMD	MoMs 2.48 (0.81 to 4.15)	All PE
Zhong 2015	6	4	n/s		LR	Early PE LR+ 1.5 (0.92 to 2.08) LR- 0.95 (0.9 to 1.0) Late PE LR+ 1.41 (0.81 to 2.46) LR- 0.95 (0.88 to 1.03)	All PE
Allen 2014	4	3	11651	bHCG	OR	1.09 (0.86 to 1.39)	All PE
Wu 2015	3	4	n/s	ADAM-12	Sensitivity and specificity	SN 26% (21-32%) SP 84% (82-86%)	All PE
Cnossen 2006	5	4	572	Uric acid	Narrative		All PE
Tabesh 2013*	8	6	2485	Vitamin D	OR	Deficiency 2.78 (1.45 to 5.33)	All PE
Christesen 2012	10	3	28726		Narrative		All PE
Hypponen 2013	6	3	6864		OR	Sufficiency OR 0.52 (0.3 to 0.89)	All PE
Aghajafari 2013	9	5	3191		OR	1.79 (1.25 to 2.58)	All PE
Harvey 2014	11	21	26856		OR	Sufficiency OR 0.78 (0.59 to 1.05) Deficiency OR 0.75 (0.48 to 1.19)	All PE
Inflammatory and immune markers							
Rebelo 2013*	23	3	4265	CRP	WMD	2.3 mg/L (1.27 to 3.34)	All PE
Lau 2013*	41	4	1940	IL6 and IL10	MD	IL-6 7.96 pg/mL (2.65 to 13.28) IL -10 5.54 pg/mL (0.69 to 10.38)	All PE
Xie 2011	43	2	Not specified		WMD	IL-6 OR 1.23 (0.93 to 1.61) WMD 6.58 (5.49 to 7.67) IL-10 OR 1.07 (0.75 to 1.52) WMD 19.3 (8.42 to 30.17)	All PE
Lau 2013*	41	4	1940	TNF alpha	MD	8.11 pg/mL (5.87 to 10.34)	All PE
Xie 2011		2	Not specified		WMD	19.63 pg/ml (18.54-20.72)	All PE
Yang 2014 (AJRI)	16	3	2230	IL-18 and IFN gamma	OR	IL -18 0.07 (-0.40 to 0.53) IFN-gamma 0.93 (0.07 to 1.79)	All PE

Markers of lipid metabolism and oxidative stress							
Gupta 2009*	26	4	1767	Lipid peroxidation	SMD	Malondialdehyde: 1.21 nmol/mL (0.76 to 1.66)	All PE
						Thiobarbituric acid-reactive substances: 1.62 (0.27 to 2.96)	
						Vitamin E -1.12 (-1.77 to -0.48)	
						Vitamin C -0.53 (-1.03 to -0.02)	
						Erythrocyte superoxide dismutase -2.37 (-4.76 to 0.03)	
Gallos 2013	29	7	5867	Hypertriglyceridaemia	MD (mmol/L)	0.78 (0.6 to 0.96)	All PE
Spracklen 2014	74	2	N/S	Hyperlipidaemia	WMD (mg/dL)	Total cholesterol 12.49 (3.44 to 21.54) HDL-C -0.48 (-3.31 – 2.34) LDL-C 3.89 (-0.19 to 7.97) Triglycerides 25.08 (14.39 to 35.77)	All PE
Cardiac and renal markers							
Afshani 2012	12	3	N/S	BNP	Narrative		All PE
Lei 2016	6	3	480	AGT II receptor auto antibodies	OR	32.84 (17.19 to 62.74)	All PE
Thrombotic markers							
Dudding 2008	6	2	6755	Factor V Leiden	OR	1.49 (1.13 to 1.96)	All PE
Kosmas 2003	18	2	4502		OR	(Vv or vv): 2.25 (1.5 to 3.38)	All PE
Rodger 2010*	10	2	21833		OR	1.23 (0.89 to 1.70)	All PE
Wang 2014	23	2	7167		OR	1.6 (1.28 to 2.0)	All PE
do Prado 2010*	12	3	8475	Antiphospholipid antibodies	OR	ACA 2.86 (1.37 to 5.98)	All PE
Abou Nassar 2011*	28	3	22300		OR	LA 2.34 (1.18 to 4.64) ACA 1.52 (1.05 to 2.2) Anti B2GP1 19.14 (6.34 to 57.77)	All PE
Other tests							

Fan 2016	12	2	905	Serum copper levels	SMD	0.69 (0.54 to 0.84)	All PE
Song 2015	26	7	2468	Serum iron	SMD	1.27 (0.76-1.78)	All PE
Zhu 2016	13	2	1013	Serum zinc	SMD	-0.61 (-0.74 to - 0.48)	All PE
Leeflang 2007	5	4	573	FFN	Narrative		All PE
Contro 2016	9	2	1646	cfFDNA	DR	68.8% (57.6 to 77.3) for 10% FPR (17-28 weeks)	All PE
Martin 2014	13	2	N/S		Narrative		All PE
Combinations of markers and models							
Zhu 2015	15	3	N/S	Combination of uterine artery PI, biomarkers and maternal characteristics	Sensitivity alone	<i>Any PE</i> All biomarkers 0.584 (0.561 to 0.608) PI+activin A 0.693 (0.592 to 0.779) PI+inhibin A 0.68 (0.59 to 0.757) PI+PAPP-A 0.566 (0.401 to 0.717) PI+PP13 0.69 (0.475 to 0.846) <b>PI+PIGF 0.88 (0.64 to 0.906)</b> <i>Early PE</i> All biomarkers 0.83 (0.794 to 0.861) <b>PI+MAP 0.894 (0.852 to 0.925)</b> PI+PAPP-A 0.729 (0.641 to 0.801) PI+PLGF 0.878 (0.784 to 0.934) PI+PP13 0.774 (0.65 to 0.863) <i>Late PE</i> All biomarkers 0.585 (0.525 to 0.642) PI+MAP 0.570 (0.503 to 0.634) PI+PLGF 0.275 (0.047 to 0.746) PI+PP13 0.536 (0.178 to 0.861) <b>PI+PAPP-A (1 study only)</b>	All, early and late onset PE

						<b>0.7 (0.55 to 0.816)</b>	
Al Rubaie 2016	29	3	27958	First trimester predictive models	Narrative		All PE
Hui 2012*	8	3	115290	Combinations of serum markers used in first trimester anomaly screening	LR	AFP+hCG >2.5 MoM LR+ 5.68 (0.73 to 43.97) LR- 0.99 (0.98 to 1.01)	All PE
Kleinrouweler 2013*	8	2	6708	Second trimester uterine artery Doppler + other tests IPD	AUC	sBP+BMI+mean PI+bilateral notching AUC 0.85 (0.67 to 1.0) sBP+BMI AUC 0.65 (0.45 to 0.84) mean PI+bilateral notching AUC 0.75 (0.56 to 0.95)	Early to onset PE
Giguere 2011*	37	2		71 different markers	Narrative		Early to onset PE
Kuc 2011	35	4	138571	Multiple serum and ultrasound markers and maternal characteristics	Narrative		All PE
<i>Multiple tests or markers assessed in single review</i>							
Duckitt 2005	52	2	N/s	Multiple clinical features	Narrative		All PE
Bartsch 2016	2	92	25356688	Multiple maternal clinical features	RR	Previous IUGR 1.4 (0.6 to 3.0) SLE 2.5 (1.0 to 6.3) Nulliparity 2.1 (1.9 to 2.4) Maternal age >35 1.2 (1.1 to 1.3) Maternal age >40 1.5 (1.2 to 2.0) Prior stillbirth 2.4 (1.7 to 3.4) CKD 2.9 (2.6 to 3.1) Multiple preg. 2.9 (2.6 to 3.1) Prior abruption 2.0 (1.4 to 2.7) Diabetes 3.7 (3.1 to 4.3) Prior PE 8.4 (7.1 to 9.9) Chronic HTN 5.1 (4.0 to 6.5)	All PE

						Antiphospholipid syndrome 2.8 (1.8 to 4.3) ART use 1.8 (1.6 to 2.1) BMI >25 2.1 (2.0 to 2.2) BMI >30 2.8 (2.6 to 3.1)	
Morris 2008	44	4	169637	AFP, hCG, estriol, PAPP-A, inhibin A, activin A	LR	AFP LR+ 2.36 (1.46 to 3.83) LR- 0.96 (0.95 to 0.98) hCG LR+ 2.45 (1.57 to 3.84) LR- 0.89 (0.83 to 0.96) Estriol LR+ 1.5 (1.02 to 2.19) LR- 0.99 (0.97 to 1.00) PAPP- A <5 <sup>th</sup> centile LR+ 2.1 (1.57 to 2.81) LR- 0.95 (0.93 to 0.98) Inhibin A LR+ 19.52 (8.33 to 45.79) LR to 0.3 (0.13 to 0.68)	All PE
Zhong 2015	6	4	n/s	PLGF, PAPP-A, hCG, PP13	LR	PLGF: LR+ 4.01 (3.74 to 4.28) PAPP-A: Early PE LR+ 2.98 (2.55 to 3.41) Late PE 1.58 (0.86 to 2.31) hCG Early PE LR+ 1.5 (0.92 to 2.08) Late PE LR+ 1.41 (0.81 to 2.46) PP13: Early PE LR 4.2 (3.69 to 4.71) All PE: LR+ 2.69 (2.05 to 3.32)	All PE
Conde-Agudelo 2004	43	4	42261	Systematic review of all screening tests	LR	Low risk RI LR+ 4.2 (3.6 to 5.1) LR – 0.6 (0.5 to 0.7) Bilateral notching LR+ 6.6 (5.8 to 7.4) LR to 0.8 (0.7 to 0.8) hCG >2.0 MoM LR+ 2.2 (1.7 to 2.9) LR to 0.8 (0.8 to 0.9) Urinary Kallikrein LR+ 4.6 (3.4 to 6.1) LR to 0.3 (0.2 to 0.6) ACA LR+ 6.7 (4.2 to 10.9) LR to 0.8 to 0.9	All PE
Meads 2008	265	3	not specified	Systematic review of 27 screening tests	Sensitivity and specificity	Bilateral notching: Sn 48% (34 to 62%) Sp 92% (87 to 95%) BMI> 34 Sn 18 (15 to 21) Sp 93 (87 to 97)	All PE



						Kallikreinuria Sn 83% (52 to 98) Sp 98% (98 to 100)	
						Cellular fibronectin Sn 50% (30 to 70) Sp 96% (94 to 98)	

Table 2d. Genetic association studies

Author Year	No. of primary studies	No. of databases searched	No. of women	Genetic factor evaluated	Reported measure of test performance	Review pooled results (95% confidence intervals)	Venice criteria	Outcome reported
Song 2013	10	2	2068	VEGF	OR	1.35 (1.11 to 1.65)	BBB	Any onset PE
Cheng 2013	8	3	1838		OR	+936C/T OR 1.52 (1.08 to 2.12) -634G/C OR 1.24 (1.03 to 1.5) -2578C/A OR 0.98 (0.82 to 1.16) -1154G/A OR 1.30 (0.94 to 1.78)	BBA	Any onset PE
Li 2014	4	3	1084		OR	OR 0.73 (0.56 to 0.95)	BAB	Any onset PE
Yang 2014 (JCMM)	12	3	5493	IL-10 polymorphisms	OR	-819c/T OR 1.28 (1.08 to 1.5) -592c/A OR 1.28 (1.03 to 1.59) -1082A/G 0.93 (0.77 to 1.13)	ACA	Any onset PE
Zhang 2016	13	6	n/s		OR	TvC OR 0.79 (0.58 to 1.07) GvA OR 0.91 (0.75 to 1.11)	ACB	Any onset PE


Lee 2014	2	11	3805		OR	1082 G/A OR 0.89 (0.73 to 1.09) -819 C/T OR 1.3 (1.01 to 1.66) -592 C/A OR 1.22 (0.97 to 1.53)	ACB	Any onset PE
Bombell 2008	16	3	2374	TNF alpha	OR	1.02 (0.86 to 1.2)	ABB	Any onset PE
Pabalan 2015	11	3	1916	HLA-G 14bp I/D polymorphism	OR	Homozygous OR 1.28 (0.93 to 1.75)	BAB	Any onset PE
Anvar 2011	5	11	1217	Glutathione S transferase polymorphisms	OR	GSTM1 OR 0.99 (0.78 to 1.25) GSTT1 OR 0.85 (0.66 to 1.10)	CCC	Any onset PE
Dai 2013*	29	5	3228	eNOS polymorphisms	OR	-786 T>C OR 1.17 (1.02 to 1.35) 4b/a OR 1.46 (1.01 to 2.1) ;	ABB	Any onset PE
Qi 2013*	33	3	10671		OR	G894T OR 1.43 (1.13 to 1.82)	ACA	Any onset PE
Shaik 2011	16	2	4485		OR	0.96 (0.75 to 1.23)	ACB	Any onset PE
Chen 2012*	18	3	N/A		OR	G849T: G allele OR 0.56 (0.33 to 0.97), T allele OR 1.17 (1.01 to 1.36)	ACB	Any onset PE

Zeng 2016	17	5	4729		OR	G894T: 1.46 (1.21 to 1.77) T-786C: 1.3 (1.07 to 1.58)	ABA	Any onset PE
Yu 2006	12	2	3513	eNOS polymorphisms	OR	Asp298 allele homozygous 1.12 (0.84-1.49)	ABA	Any onste PE
Morgan 2013*	12	3	5003	PAI1 polymorphism	OR	1.28 (1.09 to 1.50)	AAB	Any onset PE
Zhao 2012( Mol Hum Rep)	11	3	3088		OR	1.36 (1.13 to 1.64)	BAB	Any onset PE
Xia 2012*	36	4	9203	MTHFR gene C677T polymorphism	OR	1.25 (1.02 to 1.54)	ABB	Any onset PE
Li 2014*	49	4	18009		OR	White OR 1.14 (1.03 to 1.25) Asian OR 1.41 (1.11 to 1.79)	AAA	Any onset PE
Wang 2013*	51	6	17749		OR	1.28 (1.07 to 1.53)	ABB	Any onset PE
Wu 2015	45	4	88628		OR	1.157 (1.057 to 1.266)	ACB	Any onset PE
Kosmas 2004	23	2	6213		OR	1.21 (1.01 to 1.44)	ACB	Any onset PE
Zhang 2016	58	6	36438		OR	1.17 (1.05 to 1.31)	ACB	Any onset PE
Zhao 2012 (JMFNM)	8	4	3990	AGT II receptor polymorphisms	OR	+1166A>C OR 1.19 (0.96 to 1.47)	ABB	Any onset PE
Staines-Urias 2012	192	3	Not specified	AGTR1 rs186	OR	1.22 (0.96 to 1.56)	AAA	Any onset PE
Shaik 2011	17	2	3778	ACE I/D polymorphism	OR	0.987 (0.698 to 1.395)	ACB	Any onset PE
Zhong 2012	11	5	1749		OR	D allele: 1.93 (1.19 to 3.12)	BCB	Any onset PE

Chen 2012*	30	4	8340		OR	DD genotype: 1.44 (1.11 to 1.88)	ACB	Any onset PE
Zhu 2012*	23	6	3551		OR	D allele: 1.31 (1.09 to 1.57)	ACB	Any onset PE
Staines-Urias 2012	192	3	Not specified	ACE rs4646994	OR	1.17 (0.99 to 1.4)	AAA	Any onset PE
Ni 2012*	22	4	7534	AGT polymorphisms	OR	1.33 (1.09 to 1.61)	AAB	Any onset PE
Lin 2012	31	5	8669		OR	1.61 (1.22 to 2.14)	ABA	Any onset PE
Zafarmand 2008	17	3	5275		OR	1.62 (1.12 to 2.33)	ABA	Any onset PE
Staines-Urias 2012	192	3	Not specified	AGT rs699	OR	1.26 (1.00 to 1.59)	AAA	Any onset PE
Rodger 2010	6	2	14254	Prothrombin gene polymorphisms	OR	1.25 (0.79 to 1.99)	BAB	Any onset PE
Wang 2014	16	2	5558		OR	G20210A OR 181 (1.25 to 2.63)	AAB	Any onset PE


OR (Odds Ratio), RR (Relative risk), SMD (summary mean difference), WMD (weighted mean difference), AUC (area under curve), LR (likelihood ratio), Sn (sensitivity), Sp (Specificity)

BMI (body mass index), UTI (urinary tract infection), HIV (human immunodeficiency virus), CMV (cytomegalovirus), HSV to 2 (herpes simplex virus), PM<sub>2.5</sub>, (Particulate matter) CRP (C reactive protein), PI (pulsatility index), RI (resistance index), ADAM to 12 (a disintegrin and metalloprotease), TNF alpha (tumour necrosis factor alpha), IL 6,10, 18 (Interleukin 6, 10, 18) PAI to 1 (Plasminogen activator inhibitor), PP13 (placental protein 3), PAPP to A (pregnancy associated plasma protein A), hCG (human chorionic gonadotrophin), FFN (fetal fibronectin), cffDNA (cell free fetal DNA), eNOS (endothelial nitric oxide synthase), AGT(Angiotensin), UtA (uterine artery), PLGF (Placental growth factor), MAP (mean arterial pressure), SBP (systolic blood pressure), sEng (soluble endoglin), VEGF (vascular endothelial growth factor), ART (assisted reproductive technologies), TGFb (transforming growth factor beta 1), IFN (interferon), BNP (b natriuretic peptide), ACE (angiotensin converting enzyme), HLA (human leukocyte antigen), sFlt to 1 (soluble fms to like tyrosine kinase 1), MTHFR (methyltetrahydrofolate receptor)



This article is protected by copyright. All rights reserved.

Figure 1 Flow chart illustrating identification of studies included in this systematic review. \*some studies reported on markers in more than one category



This article is protected by copyright. All rights reserved.

Figure 2a - AMSTAR assessment of included studies




Figure 2b - QUIPS assessment of included studies



Number of papers included in review

Number of databases searched

Outcomes reported

Type of test evaluated

